AI Terminal
MaaT Pharma
Declaration of Voting Results & Voting Rights Announcements • Sep 9, 2024
1494_iss_2024-09-09_fa388517-b785-49ad-b6bf-765600e8bf80.pdf
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers)
Lyon, France, September 9 th , 2024 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival of patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on August 31, 2024.
Listing place: Euronext Paris
ISIN code: FR0012634822
Website: www.maatpharma.com
| Date | Total number of shares | Total number of | Total number of |
|---|---|---|---|
| comprising the share | theoretical voting | effective voting | |
| capital | (1) rights |
(2) rights |
|
| 08/31/24 | 13 918 583 |
13 918 583 |
13 890 384 |
(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform,
gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists
and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
Contacts
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 [email protected]
MaaT Pharma – Media Relations
Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 [email protected]
Trophic Communications
Jacob VERGHESE or Desmond JAMES +49 151 7441 6179 [email protected]